These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33379411)

  • 41. Improved penetration of aminoglycosides and fluorozuinolones into the aqueous humour of patients by means of Acuvue contact lenses.
    Hehl EM; Beck R; Luthard K; Guthoff R; Drewelow B
    Eur J Clin Pharmacol; 1999 Jun; 55(4):317-23. PubMed ID: 10424326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrogels in ophthalmic applications.
    Kirchhof S; Goepferich AM; Brandl FP
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):227-38. PubMed ID: 26032290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicians' perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma.
    Taniguchi EV; Kalout P; Pasquale LR; Kohane DS; Ciolino JB
    Ther Deliv; 2014 Oct; 5(10):1077-83. PubMed ID: 25418267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanotechnology-based formulations to amplify intraocular bioavailability.
    Kagkelaris K; Panayiotakopoulos G; Georgakopoulos CD
    Ther Adv Ophthalmol; 2022; 14():25158414221112356. PubMed ID: 35873277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses.
    Pelusi L; Mandatori D; Mastropasqua L; Agnifili L; Allegretti M; Nubile M; Pandolfi A
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of the latest solutions in the use of contact lenses as controlled release systems for ophthalmic drugs.
    Stiler-Wyszyńska S; Golba S; Jurek-Suliga J; Kuczkowski S
    Polim Med; 2023; 53(1):47-58. PubMed ID: 36637332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydrogel-based ocular drug delivery systems for hydrophobic drugs.
    Torres-Luna C; Fan X; Domszy R; Hu N; Wang NS; Yang A
    Eur J Pharm Sci; 2020 Nov; 154():105503. PubMed ID: 32745587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimally invasive microneedles for ocular drug delivery.
    Thakur Singh RR; Tekko I; McAvoy K; McMillan H; Jones D; Donnelly RF
    Expert Opin Drug Deliv; 2017 Apr; 14(4):525-537. PubMed ID: 27485251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(1):1-90. PubMed ID: 23074513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-delivery of Brinzolamide and Timolol from Micelles-laden Contact Lenses: In vitro and In Vivo Evaluation.
    Yang H; Zhang F; Fan Y; Zhang J; Fang T; Xing D; Zhen Y; Nie Z; Liu Y; Wang D; Li J
    Pharm Res; 2024 Mar; 41(3):531-546. PubMed ID: 38366235
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained release ocular drug delivery systems for glaucoma therapy.
    Al-Qaysi ZK; Beadham IG; Schwikkard SL; Bear JC; Al-Kinani AA; Alany RG
    Expert Opin Drug Deliv; 2023; 20(7):905-919. PubMed ID: 37249548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ophthalmic gels: Past, present and future.
    Al-Kinani AA; Zidan G; Elsaid N; Seyfoddin A; Alani AWG; Alany RG
    Adv Drug Deliv Rev; 2018 Feb; 126():113-126. PubMed ID: 29288733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review.
    Choi SW; Kim J
    Materials (Basel); 2018 Jul; 11(7):. PubMed ID: 29966397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Next-generation contact lenses: Towards bioresponsive drug delivery and smart technologies in ocular therapeutics.
    Chaudhari P; Ghate VM; Lewis SA
    Eur J Pharm Biopharm; 2021 Apr; 161():80-99. PubMed ID: 33607239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bovine serum albumin-meloxicam nanoaggregates laden contact lenses for ophthalmic drug delivery in treatment of postcataract endophthalmitis.
    Zhang W; Zu D; Chen J; Peng J; Liu Y; Zhang H; Li S; Pan W
    Int J Pharm; 2014 Nov; 475(1-2):25-34. PubMed ID: 25158220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The design of contact lens based ocular drug delivery systems for single-day use: Part (I) Structural factors, surrogate ophthalmic dyes and passive diffusion studies.
    Mahomed A; Tighe BJ
    J Biomater Appl; 2014 Sep; 29(3):341-53. PubMed ID: 24663443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.